Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries
Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of experience and adequate know-how.
This webinar focuses on choosing your regulatory strategy for Eurasian Economic Union and Commonwealth of Independent States, best practices and practical tips for market access and current regulatory status and GMP requirements.
You will learn about:
1. Commonwealth of Independent States
- Differences and overlaps with EAEU
2. Regulatory strategy in the EAEU
- Current status and main challenges
- Practical tips
3. Regulatory strategy in the CIS region
- What is the current status?
- Best practices and key tips for main challenges
- GMP requirements in EAEU and CIS
Entering EAEU or CIS markets?
Make use of our experts’ know-how to access new markets. Explore your options in a chat with one of our experts.
Who should attend?
- Global and regional RA Managers
- Regulatory Strategy Managers
- RA Partnerships Operations Manager
- QA Managers supporting RA
- RA Healthcare Compliance Managers
Duration: 25 min.
Speaker: Regulatory Affairs Project Manager, Nargiz Asgarova, who will share her expertise on regulatory strategy in EAEU and CIS regions.
Nargiz Asgarova, BSc, MBA
Regulatory Affairs Project Manager
Other content that might interest you:
Proper Publicizing in CEECs – Path to Successful Social Media Commercials
With the growth of social media network users all over the world, there is no doubt that one of the most widely used channels for promoting is social media. Statistics show that Facebook and Instagram were used actively with more than 3.4 billion people daily by January 2020. Therefore, since medical devices and over-the-counter medicines are being more often promoted by commercials on social media nowadays, there is a greater risk of hidden or misleading advertisements.
How Mergers and Acquisitions of Pharma Companies affect Regulatory Affairs?
It is easy to notice that Mergers and Acquisitions (M&A) have become a frequent occurrence in the Pharmaceutical industry, especially during the previous decades. Pharma industry is one of the leading industries in the number of M&A and the size of investments for such transitions. The value for M&A in the pharmaceutical sector was $221 billion in the first half of the year 2015. In 2019, the worth of pharma companies M&A activities have reached $357 billion.
CMC: Best Practice in Effective IND and IMPD writing
This time we will focus on technical writing and preparation for it. Also, I will provide some primary recommendations for CMC writers. The IND/IMPD being a regulatory document, has the same structure as CTD dossier. However, it includes remarkably less information on the developmental product, yet, the technical writers should understand that they will need to prepare the document in the way to reflect the actual production process and control further during the development in the later clinical phases.
